301 related articles for article (PubMed ID: 30181556)
1. The prognostic effects of somatic mutations in ER-positive breast cancer.
Griffith OL; Spies NC; Anurag M; Griffith M; Luo J; Tu D; Yeo B; Kunisaki J; Miller CA; Krysiak K; Hundal J; Ainscough BJ; Skidmore ZL; Campbell K; Kumar R; Fronick C; Cook L; Snider JE; Davies S; Kavuri SM; Chang EC; Magrini V; Larson DE; Fulton RS; Liu S; Leung S; Voduc D; Bose R; Dowsett M; Wilson RK; Nielsen TO; Mardis ER; Ellis MJ
Nat Commun; 2018 Sep; 9(1):3476. PubMed ID: 30181556
[TBL] [Abstract][Full Text] [Related]
2. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
3. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
4. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM
Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
6. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
Jiang YZ; Yu KD; Bao J; Peng WT; Shao ZM
Cancer Res; 2014 Jul; 74(13):3399-407. PubMed ID: 24924774
[TBL] [Abstract][Full Text] [Related]
7. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
[TBL] [Abstract][Full Text] [Related]
8. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
[TBL] [Abstract][Full Text] [Related]
9. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
[TBL] [Abstract][Full Text] [Related]
10. Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.
McGee SR; Tibiche C; Trifiro M; Wang E
Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):121-129. PubMed ID: 28392480
[TBL] [Abstract][Full Text] [Related]
11. Opposite Prognostic Impact of Single PTEN-loss and
Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
[TBL] [Abstract][Full Text] [Related]
12. SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers.
Puzone R; Pfeffer U
Eur J Hum Genet; 2017 Feb; 25(3):384-387. PubMed ID: 28029147
[TBL] [Abstract][Full Text] [Related]
13. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
14. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
16. The molecular diversity of Luminal A breast tumors.
Ciriello G; Sinha R; Hoadley KA; Jacobsen AS; Reva B; Perou CM; Sander C; Schultz N
Breast Cancer Res Treat; 2013 Oct; 141(3):409-20. PubMed ID: 24096568
[TBL] [Abstract][Full Text] [Related]
17. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
18. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
19. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
20. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
